We treated DM1 myoblast cells with a POSTN-neutralizing antibody and found that this antibody treatment successfully rescued the myogenesis defects, indicating that POSTN in the microenvironment is at least partially responsible for the defective myogenesis in DM1. This evidence concerns the gene POSTN and myotonic dystrophy type 1.